Key result
Euvolemic and hypervolemic hyponatremia was associated with a increased risk of death in patients with breast, colorectal, lung cancer, or lymphoma.
Why the study?
Does the development of euvolemic or hypervolemic hyponatremia reduce overall survival in patients with cancer?
Cohort (n=1,758)
Yes
Does the development of euvolemic or hypervolemic hyponatremia reduce overall survival in patients with cancer?
Euvolemic and hypervolemic hyponatremia are common across multiple cancer types and are independently associated with significantly reduced overall survival.
Answers are grounded in this paper and cite their sources.
Hyponatremia may flag higher mortality in these cancers; leaves open whether correction improves survival.
BACKGROUND: Hyponatremia is prognostic of higher mortality in some cancers but has not been well studied in others. We used a longitudinal design to determine the incidence and prognostic importance of euvolemic and hypervolemic hyponatremia in patients following diagnosis with lymphoma, breast (BC), colorectal (CRC), small cell lung (SCLC), or non-small cell lung cancer (NSCLC). METHODS: Medical record and tumor registry data from two large integrated delivery networks were combined for patients diagnosed with lymphoma, BC, CRC, or lung cancers (2002-2010) who had ≥1 administration of radiation/chemotherapy within 6 months of diagnosis and no evidence of hypovolemic hyponatremia. Hyponatremia incidence was measured per 1000 person-years (PY). Cox proportional hazard models assessed the prognostic value of hyponatremia as a time-varying covariate on overall survival (OS) and progression-free survival (PFS). RESULTS: Hyponatremia incidence (%, rate) was 76 % each, 1193 and 2311 per 1000 PY, among NSCLC and SCLC patients, respectively; 37 %, 169 in BC; 64 %, 637 in CRC, and 60 %, 395 in lymphoma. Hyponatremia was negatively associated with OS in BC (HR 3.7; P = <.01), CRC (HR 2.4; P < .01), lung cancer (HR 2.4; P < .01), and lymphoma (HR 4.5; P < .01). Hyponatremia was marginally associated with shorter PFS (HR 1.3, P = .07) across cancer types. CONCLUSIONS: The incidence of hyponatremia is higher than previously reported in lung cancer, is high in lymphoma, BC, and CRC and is a negative prognostic indicator for survival. Hyponatremia incidence in malignancy may be underestimated. The effects of hyponatremia correction on survival in cancer patients require further study.
No takes yet. Share an insight, caveat, or question.
Castillo et al. (2016) conducted a cohort in Cancer (lymphoma, breast, colorectal, lung) (n=1,758). Euvolemic and hypervolemic hyponatremia vs. No hyponatremia was evaluated on Overall survival (HR 2.7, 95% CI 2.2-3.4, p=<0.01). Euvolemic and hypervolemic hyponatremia was associated with a increased risk of death in patients with breast, colorectal, lung cancer, or lymphoma.
Synapse has enriched 10 related papers. Consider them for comparative context: